SYDNEY, July 20, 2026, 04:12 AEST
- CSL ended Friday at A$123.32, up 1.12% on the day and rising 0.35% across the week.
- The stock is trading 37% higher than its A$90 low. Volume on Friday was approximately 14% lower than the average.
- The upcoming financial report is set for August 18, with the full-year results to be released.
CSL Limited ASX:CSL has regained roughly A$16 billion in market value from its 52-week low, but last week’s slight rise lagged behind two competitors involved in plasma.
The gap is significant following a 37% rally. The upcoming operating update is set for August 18.
Shares traded on Friday totaled 1.62 million, roughly 14% under the 1.88 million average volume.
The ASX shut at 04:12 AEST Monday. Pre-open starts at 07:00, while standard trading commences at 09:59:45.
The weekly cross-market performance appeared less favorable.
| Security | July 17 close | Friday move | Week move* |
|---|---|---|---|
| CSL Limited ASX:CSL | A$123.32 | up 1.12% | up 0.35% |
| Grifols SA (BME:GRF) | €9.078 | down 0.59% | up 1.95% |
| Takeda Pharmaceutical Co (TYO:4502) | ¥5,480 | up 2.53% | up 2.26% |
| S&P/ASX 200 (INDEXASX:XJO) | 8,796.70 | down 0.50% | down 0.11% |
Weekly change reflects the difference between the closing levels of July 17 and July 10.
CSL outperformed the S&P/ASX 200 by 0.46 percentage point, but trailed Grifols by 1.60 points and Takeda by 1.91 points.
Grifols operates directly in plasma medicines. Takeda has a wider portfolio but plasma-derived treatments are still a main segment.
Grifols gained a new catalyst after launching two Phase 3 immunoglobulin trials on July 16. The disparity with peers does not represent a clear sector trend.
Friday’s performance stood out. CSL outperformed the broader market by 1.62 points, while the index dropped 0.50%.
The recovery has yet to fully materialise. CSL remains 55% beneath its 52-week high, with a market capitalisation of A$59.06 billion.
CSL reports its financial results in U.S. dollars. The company’s May update projected approximately US$15.2 billion in revenue for FY26, with NPATA expected to reach about US$3.1 billion at constant currency.
The company issued an initial impairment estimate of US$5 billion. The non-cash, pre-tax charges will cover FY26 and FY27 and are still pending audit and board clearance.
In May, interim chief executive Gordon Naylor stated that growth initiatives were delivering results. He noted that “the financial benefits will take longer than previously anticipated to materialise.”
CSL’s official calendar shows no company events scheduled this week. The company is set to release full-year results on August 18, when it plans to provide an updated impairment estimate.
External threats could take precedence before that point. Brent closed at $88.10 on Friday, rising approximately 16% over the week. Tensions between the U.S. and Iran had escalated.
The dispute also affects CSL. The company cited the issue, slower HEMGENIX growth, and increased iron competition as factors contributing to a projected US$150 million revenue headwind.
Risks exist in both directions. A quicker normalisation of U.S. immunoglobulin inventory may boost reported sales. Conversely, further declines in China albumin pricing, bigger final impairments, or fresh regional disruptions could undo the recovery.
CSL Limited is set to release its next round of hard evidence on August 18.
Related articles: ASX:CSL
